Price
CHART BY
Frequently asked questions
What is Camurus's market capitalization?
The market capitalization of Camurus is $4.25B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Camurus's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Camurus is 73.14. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Camurus?
Camurus's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.977. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Camurus's stock?
Currently, 9 analysts cover Camurus's stock, with a consensus target price of $83.18. Analyst ratings provide insights into the stock's expected performance.
What is Camurus's revenue over the trailing twelve months?
Over the trailing twelve months, Camurus reported a revenue of $213.08M.
What is the EBITDA for Camurus?
Camurus's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $67.77M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Camurus?
Camurus has a free cash flow of $38.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Camurus have, and what sector and industry does it belong to?
Camurus employs approximately 256 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Camurus's shares?
The free float of Camurus is 36.30M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.25B
- EPS (TTM)
- $0.977
- Free Float
- 36.30M
- P/E ratio (TTM)
- 73.14
- Revenue (TTM)
- $213.08M
- EBITDA (TTM)
- $67.77M
- Free Cashflow (TTM)
- $38.54M
Pricing
- 1D span
- $70.52$71.75
- 52W span
- $48.00$72.03
Analyst Ratings
The price target is $83.18 and the stock is covered by 9 analysts.
Buy
7
Hold
2
Sell
0
Information
Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.
- Employees
- 256
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- SE0007692850
- Primary Ticker
- CAMX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet